Beijing Zhongke Xianxing Medical Technology

Shenzhen Zhongke Xianxing Medical Technology (CAS-Envision) is a high-tech medical device company specializing in chip-driven medical microsystems and neural engineering. Established in 2018 as a spin-off from the Shenzhen Institute of Advanced Technology (SIAT), Chinese Academy of Sciences, the company is a leader in the development of high-resolution implantable artificial retinas. Its flagship "next-generation artificial retina" project aims to restore sight to patients suffering from Retinitis Pigmentosa and Age-related Macular Degeneration using advanced MEMS and integrated circuit technologies. Beyond ophthalmology, CAS-Envision develops brain-computer interface (BCI) solutions and integrated molecular diagnostic platforms, such as digital PCR and ELISA systems. The company maintains a state-of-the-art 6-inch MEMS flexible processing line and cleanroom facilities for the production of its sophisticated medical chips and implants.